LXO Group accelerates growth with the acquisition of Barhemsys® and secures substantial financial firepower for new acquisitions from Hayfin
Press release– January 14, 2026–LXO Group is pleased to announce the refinancing of its capital structure with Hayfin Capital Management as its new debt provider as well as the acquisition of the marketing authorization for Barhemsys (amisulpride) in the US from Eagle Pharmaceuticals
Paris, France – January 14, 2026 — LXO Group is pleased to announce the refinancing of its capital structure with Hayfin Capital Management (“Hayfin”) as its new debt provider. This refinancing marks a significant milestone for LXO Group in the pursuit of its strategic objectives by unlocking substantial fresh capital for its ambitious acquisition plans.
Hayfin Capital Management, a leading alternative asset management firm, will support both LXO Group’s organic growth initiatives and its ambitious M&A plans, enabling the company to identify, execute and integrate complementary assets that align with its focus on established pharmaceutical products with growth potential. The new partnership underscores Hayfin’s confidence in LXO Group’s business model and Management’s ability for sustained value creation across its portfolio of products.
“The partnership with Hayfin, alongside our majority shareholders Stanley Capital Partners (“SCP”), significantly strengthens LXO Group and provides the required resources to execute our exciting long-term growth strategy and value creation plan” said Karine Pinon, CEO of LXO Group.
“We are delighted to partner with a successful business such as LXO Group and, together with its majority shareholders, support Management on the delivery of an ambitious plan,” said Miloš Čoko, Managing Director at Hayfin.
In tandem with this refinancing, LXO Group is pleased to announce the acquisition of the marketing authorization for Barhemsys (amisulpride) in the US from Eagle Pharmaceuticals, further bolstering its portfolio in hospital-based therapeutics. Barhemsys is a fast-growing product with long-term patents indicated for the treatment of Postoperative Nausea and Vomiting (PONV) alone or with another antiemetic in patients with or without prior prophylaxis. Approved in February 2020 and launched in the US in November 2020, Barhemsys is the only FDA-approved treatment for Breakthrough PONV, addressing a critical need in post-surgical care by offering a targeted, effective option to manage this common complication that affects millions of patients annually.
“This acquisition enables LXO Group to scale its presence in the US through a direct commercial organization focused on hospital distribution, while leveraging a differentiated, patent-protected product with the potential to deliver double-digit growth over the next five years,” said Karine Pinon, CEO of LXO Group.
“The deployment of a direct hospital sales force around Barhemsys significantly enhances our US commercial capabilities and creates immediate synergies with our existing US portfolio, with all products being distributed in the same distribution channel” said Jason Jones, Head of US Operations at LXO Group.
“We are pleased to welcome Hayfin as a new partner for LXO Group and SCP, and the acquisition of Barhemsys is a great starting point to launch this next phase of accelerated growth for LXO Group,” said Patrick von Hargutt, Founding Partner at SCP.
About LXO Group – LXO Group is a leading integration platform for mature medicines that are essential for millions of patients and healthcare professionals. As a lifecycle management specialist with a focus on Cardiovascular (CV) and Central Nervous System (CNS) products, its portfolio consists of category-leading branded products addressing chronic diseases with a history of highly sustainable revenues and robust organic growth.
About Hayfin Capital Management – Hayfin Capital Management (“Hayfin”) is a leading alternative asset management firm with c. €35 billion in assets under management. Hayfin focuses on delivering attractive risk-adjusted returns for its investors across its private debt, liquid credit and private equity solutions businesses.
Hayfin has a diverse international team of over 200 experienced industry professionals with offices globally, including headquarters in London and offices in Chicago, Dubai, Frankfurt, Luxembourg, Madrid, Milan, Munich, New York, Paris, Stockholm, San Diego and Tokyo.
About Stanley Capital Partners – (“SCP”) is an investment firm focused on building and scaling businesses and platforms in sustainable growth sectors. The firm partners with management teams, in majority and minority transactions, to transform and grow companies to unlock their potential.
Forward-Looking Statements – This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, including statements regarding LXO Group’s future growth, M&A plans, and the anticipated benefits of the refinancing and acquisition. These statements are based on current expectations and beliefs and involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied. Such factors include, but are not limited to, economic conditions, regulatory approvals, integration risks, market acceptance of products, and competitive pressures. LXO Group undertakes no obligation to update these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.
